Post by ronykimm on Dec 30, 2021 2:42:17 GMT -5
Brentuximab vedotin is introduced as a type of targeted therapy known as an antibody–drug conjugate. The FDA has approved brentuximab vedotin injection to treat some patients with Hodgkin lymphoma. This medication is also approved to treat some patients with systemic anaplastic large cell lymphoma (ALCL), a type of T-cell non-Hodgkin lymphoma. Brentuximab vedotin is administered as an infusion into a vein. A health specialist will administer you this injection.